Board Meeting7 Sept 2026, 07:41 pm
Tavexia Lifecare Appoints New Auditor, Eyes Meyonex Pharma Acquisition
AI Summary
Tavexia Lifecare Ltd announced a significant board meeting outcome, including the acceptance of resignation from its statutory auditor, M/s SSRV & Associates. The company has appointed M/s DEVAM & Associates LLP as the new statutory auditor for a five-year term, subject to member approval. Additionally, the board approved the re-appointment of Mrs. Khushboo Vasudev as an Independent Director for a second five-year term. A key development is the board's authorization to explore and evaluate the acquisition of up to 60% equity share capital in Meyonex Pharmaceuticals Limited, with directors authorized to conduct due diligence and negotiations.
Key Highlights
- New statutory auditor appointed for a five-year term.
- Independent Director re-appointment approved for a second term.
- Board authorized to explore acquisition of Meyonex Pharmaceuticals.
- Directors empowered to negotiate acquisition terms.
- Resignation of previous statutory auditor accepted.
Price Impact
More from SATTVASUKU